BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
The Company will host a conference call on
To dial into the conference call, please dial +1-866-744-5399 from the
About
The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a clinical trial collaboration agreement with MSD (
For additional information on
Contact:
+1-212-915-2564
tim@lifesciadvisors.com
or
+972-54-476-4945
moran@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2021-results-on-november-18-2021-301422992.html
SOURCE